Sign in

Research summary ·

Disease Stabilization with MEK Inhibitors in NF1-Associated Plexiform Neurofibromas: A Systematic Review and Meta-Analysis with Subgroup Analyses by Age and Study Design.

Written based on 1 research study on PubMed, searched on 15 Nov 2026.

What was studied

This review looked at MEK inhibitors for plexiform neurofibromas in NF1. These are tumors that can grow in people with NF1. MEK inhibitors are a type of targeted drug. The team searched for past work on this treatment. They found 23 studies with 769 people in all. They pooled the data to get overall rates. They also compared children with adults, and trials with real-world care.

What they found

Tumors shrank in some people, the authors say. Shrinking was seen more often in clinical trials than in real-world groups. Children and adults did not differ in a clear way. While on the drug, nearly all people had their disease held steady. Very few people had their tumors grow during treatment. Serious side effects, grade 3 or worse, happened in some people.

What it means for patients

The authors link these drugs to high rates of disease control. Tumor growth was rare while people took them. This held in both trials and real-world settings. The main gain seems to be keeping tumors stable. Tumor shrinking was more common in trials than in real-world care.

Why it is not certain yet

The data on shrinking and side effects were not the same across studies. Real-world groups showed less shrinking than trials did. The rates for control and growth cover only time on the drug. The abstract does not give results after the drug stops. A review can only be as good as the studies in it.

Source

Disease Stabilization with MEK Inhibitors in NF1-Associated Plexiform Neurofibromas: A Systematic Review and Meta-Analysis with Subgroup Analyses by Age and Study Design.

PubMed · PMID 42467350

We restate facts from the source record in our own words. The original wording belongs to its publisher.

This page is not medical advice. Talk to your doctor about your own care.

Back to Neurofibromatosis type 1 publications